Subash C. Jonnalagadda

This study identifies KS100, a pan-ALDH inhibitor, as effective in reducing ALDH expression and viability of multiple myeloma cells, particularly ALDH+/CD138- stem-like cells, potentially overcoming relapse.

This paper identifies KS18, a Mcl-1 inhibitor, as a potential treatment for multiple myeloma, showing it enhances apoptosis and overcomes resistance to bortezomib and venetoclax in resistant cells and mouse models.

This paper develops a novel BTK inhibitor, KS151, which effectively targets MM stem cell-like cells and enhances the response to chemotherapeutic agents.